141
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Lack of COPD-Related Follow-Up Visits and Pharmacological Treatment in Swedish Primary and Secondary Care

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 1769-1780 | Received 26 Apr 2022, Accepted 18 Jul 2022, Published online: 09 Aug 2022

Figures & data

Table 1 Baseline Characteristics of the Study Population

Table 2 Regular Follow-Up Visits for COPD (Within 15 Months Post-Index) and Post-Exacerbation Visits (Within 15 Months Post-Exacerbation) in Primary and Secondary Care and in Total

Figure 1 Probability of COPD-related follow-up visit after index date accounting for competing risks (exacerbation and death).

Figure 1 Probability of COPD-related follow-up visit after index date accounting for competing risks (exacerbation and death).

Figure 2 Probability of COPD-related follow-up visit after the first exacerbation (A) moderate, (B) severe) accounting for competing risks (exacerbation and death).

Figure 2 Probability of COPD-related follow-up visit after the first exacerbation (A) moderate, (B) severe) accounting for competing risks (exacerbation and death).

Figure 3 Probability of COPD follow-up visits and exacerbation within 15 months after the event, across calendar year accounting for competing risks (exacerbation and death).

Figure 3 Probability of COPD follow-up visits and exacerbation within 15 months after the event, across calendar year accounting for competing risks (exacerbation and death).

Figure 4 COPD treatment patterns during follow-up at 0–3, 3–6, 6–9, 9–12 and 12–15 months after index date stratified by (A) without COPD visit (n=11,387) and (B) with COPD visit (n=7416).

Figure 4 COPD treatment patterns during follow-up at 0–3, 3–6, 6–9, 9–12 and 12–15 months after index date stratified by (A) without COPD visit (n=11,387) and (B) with COPD visit (n=7416).